ClinicalTrials.gg
CompletedNCT06040944Updated Sep 18, 2023

Antipsychotic Induced Hyperprolactinemaia as Risk Factor for Periodontitis in Schizophrenic Patients

An observational study in Schizophrenia Spectrum and Other Psychotic Disorders and Periodontal Diseases, sponsored by Fayoum University. Completed at 1 site in Egypt. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2023-09-18.

Primary conditionSchizophreniaRegistry: Schizophrenia Spectrum and Other Psychotic DisordersReclassifiedWhy we changed it
Registry
Schizophrenia Spectrum and Other Psychotic Disorders — the first condition term the registry derived for this study.
ClinicalTrials.gg
Schizophrenia
Why
  1. The study's listed conditions name Schizophrenia, a narrower term within Schizophrenia Spectrum and Other Psychotic Disorders.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Fayoum University · Observational

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
64
Ages
20 Years and older
Sex
All
01

Study summary

The aim of the present cohort retrospective study is to explore the effect of antipsychotics on periodontal health and the possible effect of antipsychotic-induced hyperprolactinemia as a risk factor for periodontal disease progression in schizophrenic patients.

The study population consisted of three groups: Group A (n = 21): schizophrenic patients who have been taking "prolactin inducing" antipsychotics for at least 1 year, Group B (n = 21): schizophrenic patients who have been taking "prolactin sparing" antipsychotics for at least 1 year and Group C (n = 22): newly diagnosed schizophrenic patients and/or patients who did not receive any psychiatric treatment for at least 1 year.

The study groups underwent an assessment of periodontal condition in terms of pocket depth (PD), clinical attachment loss (CAL), gingival recession, tooth mobility, and bleeding on probing (BOP). Also, bone mineral density was evaluated using DEXA scans and the serum prolactin level was measured by automated immunoassay.

Read the detailed description

Background and objective: The aim of the present cohort retrospective study is to explore the effect of antipsychotics on periodontal health and the possible effect of antipsychotic-induced hyperprolactinemia as a risk factor for periodontal disease progression in schizophrenic patients.

Methods

  1. Study design and setting:

    The current study is a cohort retrospective study that will be performed on schizophrenic patients. All subjects will be recruited from the outpatient clinic of the department of Psychiatry-Faculty of Medicine- MUST University. The patients' database from the department of psychiatry will be filtered, and all patients with a diagnosis of schizophrenia according to DSM-IV-TR criteria for schizophrenia and fulfilling eligibility criteria will be contacted. Also, outpatients newly diagnosed with schizophrenia will be included. Those who agree to be enrolled in the study will sign a written informed consent. For patients previously diagnosed with schizophrenia, medication data will be acquired from prescription files, including the type and duration of the prescribed antipsychotic or other medications.

    Psychiatric assessment and recording of demographic variables such as age, gender, duration of psychiatric disease, and type and duration of antipsychotic medication will be performed by the second investigator (EM.A). Then, all subjects will be referred, with their records and files, to the Faculty of Dentistry at ACU University for periodontal assessment and sample collection.

  2. Eligibility criteria:

    The included patients are those: 1) with the diagnosis of schizophrenia; 2) over 20 years old; 3) who did not receive any periodontal treatment for the past year; and 4) with at least 20 remaining teeth. To avoid potential confounding factors, the excluded patients are: 1) those with systemic conditions that may affect periodontal status such as; DM, CVS, metabolic syndrome, osteoporosis, AIDS, and chronic alcoholism (3, 4, 17); 2) those with local factors that may aggravate and predispose for periodontal diseases, such as orthodontic and prosthetic appliances, parafunctional habits, and heavy smoking (4, 23-25); and 3) those receiving any systemic medication and/or systemic antibiotics for the past 6 months. Additionally, exclusion criteria involved 4) patients undergoing any type of periodontal treatment for the past year; 5) patients within the childhood and adolescent psychiatry section; and 6) patients who received antipsychotic medication for ≥ 12 months.

  3. Estimating the sample size:

    The sample size was calculated considering type I error (α) of 0.05 and power (1-β) of 0.9. Based on a previous study by (16) that used proportions, inequality, and two independent groups (Fisher's exact test) to compare patients with a pocket depth of 4 mm to those with no pocket depth identified in patients receiving antipsychotics 12 months with effect size, the sample size was calculated and found to be a total of 64 patients. The application G*Power 3.1.9.7 [16] was used to determine the sample size needed for the study.

  4. Participants:

The study population will be divided into three groups: Exposure groups will be divided according to their "prolactin-inducing" or "prolactin sparing" effect (26-36). Group A (n = 21): schizophrenic patients that have been taking antipsychotic medication that may induce hyperprolactinemia (FGAs and SGAs; amisulpride, risperidone, and paliperidone) for at least 1 year, group B (n = 21): schizophrenic patients who have been taking antipsychotics that do not have a significant effect on serum prolactin levels (in SGAs, clozapine, quetiapine, olanzapine, ziprasidone, and aripiprazole) for at least 1 year and Group C (n = 22): newly diagnosed schizophrenic patients and/or patients who did not receive any psychiatric treatment for at least 1 year.

[4] Outcome measurements: The primary outcome was the assessment of periodontal condition in all study groups measured in terms of pocket depth (PD), tooth mobility, clinical attachment loss (CAL), gingival recession, and bleeding on probing (BOP), while the secondary outcomes were evaluation of BMD and the serum prolactin level (measured by automated immunoassay in ng/ml).

[6]Assessment of clinical data and patient condition: Assessment of mental health: The Positive and Negative Syndrome Scale (PNSS) (37) was used to evaluate each patient's clinical history and current mental health state.

Periodontal evaluation:

All teeth were evaluated and recorded. The means for the following parameters were computed: pocket depth (PD), clinical attachment loss (CAL), and bleeding on probing (BOP) (38, 39). Using a manual periodontal probe (Williams' periodontal probe, PCP-12; Hu-Friedy, Chicago, IL, USA), PD and CAL measurements were collected on six surfaces per tooth (mesio-buccal, mid-buccal, disto-buccal, and mesio-lingual, mid-lingual, disto-lingual, or palatal surface).While CAL measures the distance between the cement-enamel junction of the tooth and the deepest aspect of the pocket, probing pocket depth measures the distance between the gingival margin and the deepest part of the pocket. Total mean PD of the six locations for each tooth was computed for each patient and distance was recorded to the nearest millimeter (40). Sulcus depths between 0 and 2 mm were regarded as normal (41). Gingival recession was measured from the CEJ to the marginal border of the soft tissue on the buccal and lingual sides of each tooth. The total mean number of recessions per tooth for each patient was used to record tooth recessions. Gingival recession, if present, was only used to calculate CAL by its addition to PD.

Four surfaces per tooth were examined for BOP readings (mesial, distal, buccal, and lingual or palatal surface). Bleeding on probing was examined directly after the PD measurement and was reported as absent (0) or present (1). 30 seconds after applying the periodontal probe). The proportion of teeth displaying BOP was recorded.

Generalized mild periodontitis is defined as >30% of remaining teeth with PD 5 mm and 7 mm, as per the 2015 Update to the 1999 Classification of Periodontitis. Severe periodontitis was defined as a probing depth (PD) of 7 mm, with localised periodontitis involving 30% of remaining teeth and generalised periodontitis involving >30% of remaining teeth (42) .

Assessment of bone mineral density:

Dual-energy X-ray absorptiometry (DEXA scan) is an advanced technology that could detect bone mineral density. The GE Lunar Prodigy densitometer was used to perform this test.To determine what constitutes healthy bone, we utilized the World Health Organization's criteria: a T score of -1 indicates normal bone, a T score between -1 and -2.5 indicates osteopaenia, and a T score of -2.5 indicates osteoporosis.

Measurement of serum prolactin level:

Blood will be withdrawn from all patients to determine the fasting serum prolactin level. Prolactin concentrations in blood will be measured in a faculty laboratory by automated immunoassay methodology (43).

7] Data collection and management: Periodontal assessment will be carried out by the primary investigator (S.R.), who will be unaware of the patient's psychological status and records (to avoid potential bias). The third investigator (M.C.) will collect all patient records to perform the final analysis.

STATISTICAL METHODS:

Quantitative (continuous) variables were expressed as mean ± SD. As the quantitative variables were not normally distributed, the Kruskal-Wallis test (a non-parametric test) was used to compare them among the 3 study groups. A post hoc analysis was done for variables that showed a statistically significant difference in the Kruskal-Wallis test using Dwass-Steel-Critchlow-Fligner pairwise comparisons. As for qualitative variables (categorical), the chi-square test was used to compare them among the 3 study groups, and values were expressed as percentages. Also, linear regression analysis was performed to study the relation between 2 quantitative variables (serum prolactin level and PD measurements), while ordinal logistic regression was used to relate one quantitative (serum prolactin level) and one qualitative (BMD or grades of periodontitis) variables.

02

Conditions studied

  • Schizophrenia Spectrum and Other Psychotic Disorders
  • Periodontal Diseases

Keywords

  • schizophrenia
  • antipsychotics
  • periodontal disease
  • hyperprolactinemia
03

In context

Schizophrenia Reclassified

3,563 studies on the registry are indexed under Schizophrenia; 491 are open to participants now.

This study's enrollment of 64 is below the median of 178 across 506 observational studies indexed under Schizophrenia.

Browse Schizophrenia studies →

Lead sponsor

Fayoum University is the lead sponsor of 148 studies on the registry; 44 are open to participants now.

Compared within Schizophrenia, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Schizophrenia Spectrum and Other Psychotic Disorders. The counts are of registry records indexed under each term, refreshed daily. How we classify →

04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Sampling method
Non-probability sample

Study population

diagnosis of schizophrenia according to DSM-IV-TR criteria for schizophrenia

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. with the diagnosis of schizophrenia
  2. over 20 years old
  3. did not receive any periodontal treatment for the past year
  4. with at least 20 remaining teeth.

Exclusion criteria

Exclusion Criteria:

  1. with systemic condition that may affect periodontal status such as; DM, cardiovascular diseases, metabolic syndrome, osteoporosis, AIDS and chronic alcoholism
  2. having local factors that may aggravate and predispose for periodontal diseases such as; orthodontic and prosthetic appliances, parafunctional habits, and heavy smoking
  3. receiving any systemic medication and/or systemic antibiotics for the past 6 months.
  4. patients undergoing any type of periodontal treatment for the past year and
  5. within childhood and adolescence psychiatry section.
05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
64 participants (actual)
Patient registry
No

Groups and cohorts

  • Exposure 1

    Schizophrenic patients that have been taking antipsychotic drugs inducing hyperprolactinemia (FGAs and the SGAs; amisulpride, risperidone and paliperidone) for at least 1 year

    Drug: antipsychotic drugs inducing hyperprolactinemia

  • Exposure 2

    Schizophrenic patients that have been taking antipsychotics sparing hyperprolactinemia (In SGAs; clozapine, quetiapine, olanzapine, ziprasidone and aripiprazole) for at least 1 year

  • Non exposure (basline)

    Newly diagnosed schizophrenic patients and/ or patients did not receive any psychiatric treatment for at least 1 year

Interventions

  • Drugantipsychotic drugs inducing hyperprolactinemia

    not exposed

    Also known as: antipsychotic drugs not inducing hyperprolactinemia

06

What researchers measure

Primary outcomes

  1. Severity of periodontal diseases

    The primary outcome will be the assessment of periodontal condition in all study groups measured in terms of Pocket depth (PD), clinical attachment loss (CAL) (both measured using graduated periodontal probe in mm)

    Time frame: 1 months

  2. gingival condition

    bleeding on probing (BOP) using scores from 0-3

    Time frame: 1 months

  3. tooth mobility

    in mm

    Time frame: 1 months

Secondary outcomes

  1. Serum prolactin level

    measurement of serum prolactin level ( measured by automated immunoassay in ng/ml)

    Time frame: 1 months

07

Study locations

1 site
  • Rania Hassan Shalby
    Giza, Egypt
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Sep 18, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06040944
Lead sponsor
Fayoum University
Responsible party
Rania Hassan Shalby (Lecturer of Oral Medicine, Fayoum University) — Principal investigator
First posted
Sep 18, 2023
Start date
Sep 1, 2022
Primary completion
Oct 1, 2022
Completion
Nov 1, 2022
Last update
Sep 18, 2023

Study contacts

Rania H Shalby, phd
principal investigator · Faculty of Dentistry-Fayoum University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion